Views

CrossRef citations to date

Altmetric

Original Article

Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease

Yongzhong Wang Cardiac Catheterization Laboratory, The Heart Centre, Copenhagen, Denmark

Rasmus S. Ripa Cardiac Catheterization Laboratory, The Heart Centre, Copenhagen, Denmark

Erik Jørgensen Cardiac Catheterization Laboratory, The Heart Centre, Copenhagen, Denmark

Birger Hesse Department of Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark

Steen Mortensen Cardiac Catheterization Laboratory, The Heart Centre, Copenhagen, Denmark

Jens Kastrup Cardiac Catheterization Laboratory, The Heart Centre, Copenhagen, DenmarkCorrespondence[email protected]

Figures & data

Table I. Demographics and clinical data of the patients treated with Placebo, VEGF, low dose G-CSF (lG-CSF) and VEGF-A₁₆₅- combined with high dose G-CSF (hG-CSF).

Download CSV Display Table

Figure 1. A) Circulating CD34+ cells (10³/mL) from baseline to day 28. B) Increase in circulating CD45 − CD34− relative to the baseline value in each group. Data in panel A are previously published. Citation12, Citation13

Figure 1. A) Circulating CD34+ cells (103/mL) from baseline to day 28. B) Increase in circulating CD45 − CD34− relative to the baseline value in each group. Data in panel A are previously published. Citation12, Citation13

Figure 2. Relative increase in circulating CD45 − CD34− subtype (A) CD105+ and CD45-CD34- cell types with endothelial markers (B) CD31+ (C) CD144+ (D) KDR+ and (E) CXCR4+ in the first month after G-CSF treatment. *p < 0.05 day 3 and day 7 versus day 1 in low dose group. #p < 0.05 day 3 and day 7 versus day 1 in high dose group.

Table II. Plasma concentrations of VEGF and stromal-derived factor-1 (SDF-1) in patients treated with placebo, plasmid VEGF-A₁₆₅, G-CSF or VEGF-A₁₆₅- combined with G-CSF the first month after treatment.

Download CSV Display Table

Table III. Correlations between peak value of mobilized cells and change in clinical characteristics from baseline to follow-up for patients treated with G-CSF or VEGF-A₁₆₅- combined with G-CSF.

Download CSV Display Table

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease

Table I. Demographics and clinical data of the patients treated with Placebo, VEGF, low dose G-CSF (lG-CSF) and VEGF-A₁₆₅- combined with high dose G-CSF (hG-CSF).

Table II. Plasma concentrations of VEGF and stromal-derived factor-1 (SDF-1) in patients treated with placebo, plasmid VEGF-A₁₆₅, G-CSF or VEGF-A₁₆₅- combined with G-CSF the first month after treatment.

Table III. Correlations between peak value of mobilized cells and change in clinical characteristics from baseline to follow-up for patients treated with G-CSF or VEGF-A₁₆₅- combined with G-CSF.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease

Figures & data

Table I. Demographics and clinical data of the patients treated with Placebo, VEGF, low dose G-CSF (lG-CSF) and VEGF-A165- combined with high dose G-CSF (hG-CSF).

Table II. Plasma concentrations of VEGF and stromal-derived factor-1 (SDF-1) in patients treated with placebo, plasmid VEGF-A165, G-CSF or VEGF-A165- combined with G-CSF the first month after treatment.

Table III. Correlations between peak value of mobilized cells and change in clinical characteristics from baseline to follow-up for patients treated with G-CSF or VEGF-A165- combined with G-CSF.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table I. Demographics and clinical data of the patients treated with Placebo, VEGF, low dose G-CSF (lG-CSF) and VEGF-A₁₆₅- combined with high dose G-CSF (hG-CSF).

Table II. Plasma concentrations of VEGF and stromal-derived factor-1 (SDF-1) in patients treated with placebo, plasmid VEGF-A₁₆₅, G-CSF or VEGF-A₁₆₅- combined with G-CSF the first month after treatment.

Table III. Correlations between peak value of mobilized cells and change in clinical characteristics from baseline to follow-up for patients treated with G-CSF or VEGF-A₁₆₅- combined with G-CSF.